<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="264">
  <stage>Registered</stage>
  <submitdate>10/08/2001</submitdate>
  <approvaldate>10/08/2001</approvaldate>
  <nctid>NCT00022126</nctid>
  <trial_identification>
    <studytitle>Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia</studytitle>
    <scientifictitle>A Study of Modified Augmented BFM Therapy for Infants With Acute Lymphoblastic Leukemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>COG-AALL01P1</secondaryid>
    <secondaryid>AALL01P1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - asparaginase
Treatment: drugs - cyclophosphamide
Treatment: drugs - cyclosporine
Treatment: drugs - cytarabine
Treatment: drugs - daunorubicin hydrochloride
Treatment: drugs - dexamethasone
Treatment: drugs - doxorubicin hydrochloride
Treatment: drugs - mercaptopurine
Treatment: drugs - methotrexate
Treatment: drugs - methylprednisolone
Treatment: drugs - pegaspargase
Treatment: drugs - thioguanine
Treatment: drugs - vincristine sulfate
Treatment: surgery - allogeneic bone marrow transplantation
Treatment: other - radiation therapy

Experimental: Modified Augmented BFM Therapy - 


Treatment: drugs: asparaginase


Treatment: drugs: cyclophosphamide


Treatment: drugs: cyclosporine


Treatment: drugs: cytarabine


Treatment: drugs: daunorubicin hydrochloride


Treatment: drugs: dexamethasone


Treatment: drugs: doxorubicin hydrochloride


Treatment: drugs: mercaptopurine


Treatment: drugs: methotrexate


Treatment: drugs: methylprednisolone


Treatment: drugs: pegaspargase


Treatment: drugs: thioguanine


Treatment: drugs: vincristine sulfate


Treatment: surgery: allogeneic bone marrow transplantation


Treatment: other: radiation therapy


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Establish whether the CCG Augmented Regimen (AR) can be successfully administered in the infant age group</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Grade 3 or 4 non-hematologic toxicity rates</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Event-free survival</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Diagnosis of previously untreated acute lymphoblastic leukemia (ALL) or acute
             undifferentiated leukemia

               -  CNS or testicular disease allowed

          -  No L3 sIg+ ALL or acute myelogenous leukemia

          -  At least 36 weeks gestation for congenital ALL

        PATIENT CHARACTERISTICS:

        Age:

          -  Under 366 days at diagnosis

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Steroid therapy within 48 hours of study allowed if complete blood counts and lumbar
             puncture results known

          -  No chronic steroid treatment for other disease

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Not specified

        Other:

          -  No other concurrent cytotoxic therapy</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>1</inclusivemaxage>
    <inclusivemaxagetype>Year</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>6</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,WA</recruitmentstate>
    <hospital>Women's and Children's Hospital - North Adelaide</hospital>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>5006 - North Adelaide</postcode>
    <postcode>6006 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Children's Oncology Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Giving the drugs in different combinations may kill more cancer
      cells. Bone marrow transplantation allows the doctor to give higher doses of chemotherapy and
      kill more cancer cells.

      PURPOSE: Phase II trial to compare the effectiveness of combination chemotherapy with or
      without donor bone marrow transplantation in treating infants who have previously untreated
      acute lymphoblastic leukemia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00022126</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul S. Gaynon, MD</name>
      <address>Children's Hospital Los Angeles</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>